Evidence map›Paper›PMID 34826011›Full record

ArticleInternational journal of clinical oncology2022

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.

Liudmila V Fedorova, Kirill V Lepik, Nikita P Volkov, Polina V Kotselyabina, Evgenia S Borzenkova, Marina O Popova, Anastasia V Beynarovich, Vadim V Baykov, Andrey V Kozlov, Ivan S Moiseev and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Liudmila V FedorovaRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia. MD.FedorovaL@gmail.com.ORCID http://orcid.org/0000-0002-3275-219X
Kirill V LepikRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Nikita P VolkovRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Polina V KotselyabinaRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Evgenia S BorzenkovaRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Marina O PopovaRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Anastasia V BeynarovichRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Vadim V BaykovRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Andrey V KozlovRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Ivan S MoiseevRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Natalia B MikhailovaRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
Alexander D KulaginRM Gorbacheva Research Institute, Pavlov University, 6-8 L'va Tolstogo, 197022, St. Petersburg, Russia.
First Pavlov State Medical University of St. Petersburg · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTherapy of patients with relapsed and refractory classic Hodgkin lymphoma (r/r cHL) after PD-1 inhibitors failure remains an unresolved issue. The aim of this study was to evaluate the efficacy and safety of the combination of nivolumab with brentuximab vedotin (Nivo + BV) after nivolumab monotherapy failure.

methodsThis study retrospectively analyzed 21 patients with r/r cHL who were treated with the combination of Nivo + BV after Nivo failure. The response was evaluated by PET-CT scan according to the LYRIC criteria. Adverse events (AEs) were assessed according to NCI CTCAE v.4.03.

resultsMedian follow-up was 19 (9-47) months. The ORR was 57%. The median OS was not reached, 24 month OS was 80% (95% CI 50-93%). Median PFS was 12 months with 24 month PFS of 31% (95% CI 12-53%). Any grade AEs were observed in 12 patients (63%), 3-4 grade AEs in 2 patients (10%). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after Nivo + BV was performed in 8 (38%) patients. The median time between Nivo + BV and allo-HSCT was 8 (5-21) months.

conclusionsCombination of Nivo + BV in r/r cHL after nivolumab monotherapy failure is potentially an effective and safe approach.

Indexed as

Hodgkin DiseaseNivolumabBrentuximab VedotinHumansPositron Emission Tomography Computed TomographyRetrospective StudiesBrentuximab VedotinNivolumabBrentuximab vedotinHodgkin lymphomaImmunotherapyNivolumabPD-1 inhibitorsRelapsed and refractory disease

Identifiers

PMID34826011
PMCPMC8619646
OpenAlexW3217026837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.